Gosset Ownership
Private
Employees
~2
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
AkiraBio General Information
AkiraBio develops molecularly targeted therapies using its proprietary Gene Programming™ platform to modulate gene expression at the DNA level. Its lead program targets DNMT1 and hemoglobin for treating sickle cell disease and related hematological conditions. The most advanced asset, NSC777586, is in preclinical development with a focus on increasing fetal hemoglobin levels to treat sickle cell disease and thalassemia. No published clinical results are available as of May 2025.
Contact Information
Primary Industry
Biotech
Corporate Office
Wellesley, Massachusetts
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Augusta University listed as originator organization for some assets/patents.
AkiraBio Funding
No funding data available
To view AkiraBio's complete valuation and funding history, request access »